KB-1130

Camidanlumab

Background

Camidanlumab is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). Camidanlumab tesirine (Cami-T or ADCT-301) is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin. The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Specifications

Catalog Number:
KB-1130
Cell Line Name:
Camidanlumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD25
Species Reactivity:
Human
Application:
ELISA | FACS | KD
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS | KD

References

1.Collins G, Horwitz S, Hamadani M, Samaniego F, Spira A, Caimi P, Davies A, et al. Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) 2.Spriano F, Tarantelli C, Golino G ,Gaudio E, Scalise L, Cascione L, Zucca E, et al. The Anti-CD25 Antibody-Drug Conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity Both as Single Agent and In Combination in Lymphoma Cell Lines. Presented during the 15th International Conference on Malignant Lymphoma (ICML), held June 18 – 22, 2019, Lugano, Switzerland.
Please enable JavaScript in your browser to complete this form.